Straumann Holding AG (OTCMKTS:SAUHY – Get Free Report) saw a significant drop in short interest during the month of August. As of August 14th, there was short interest totaling 1,001 shares, a drop of 80.6% from the July 30th total of 5,152 shares. Based on an average daily trading volume, of 47,320 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.
Straumann Price Performance
Shares of OTCMKTS SAUHY opened at $11.41 on Wednesday. The firm has a fifty day moving average price of $12.58 and a 200-day moving average price of $11.70. Straumann has a 1 year low of $9.44 and a 1 year high of $13.61.
Analyst Ratings Changes
SAUHY has been the subject of a number of recent analyst reports. BMO Capital Markets started coverage on Straumann in a research report on Wednesday, July 8th. They issued an “outperform” rating for the company. Citigroup reiterated a “sell” rating on shares of Straumann in a research note on Thursday, July 9th. Barclays reissued an “overweight” rating on shares of Straumann in a report on Thursday, June 18th. Deutsche Bank Aktiengesellschaft downgraded shares of Straumann from a “buy” rating to a “hold” rating in a research report on Friday, August 21st. Finally, Morgan Stanley restated an “underweight” rating on shares of Straumann in a report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Straumann Company Profile
Straumann (OTCMKTS:SAUHY) is a Swiss-based dental technology company that develops, manufactures and markets restorative, regenerative and digital solutions for dental professionals. The company’s core offerings center on implant-supported restorations and components, biomaterials used for bone and soft-tissue regeneration, and a range of prosthetic products used by dentists and dental laboratories to restore oral function and aesthetics.
In addition to implant and biomaterial product lines, Straumann provides digital dentistry solutions that support treatment planning and workflows.
Further Reading
- Five stocks we like better than Straumann
- 5 Stocks to Buy in September Before Wall Street Catches On
- PDD Beat Earnings—So Why Did the Stock Still Fall?
- Tariffs Are Back in Focus: 3 Stocks With a Home-Field Advantage
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
Receive News & Ratings for Straumann Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Straumann and related companies with MarketBeat.com's FREE daily email newsletter.
